INTRODUCTION

Immunosuppressive therapy after solid organ transplantation has been steadily improved over the last few decades and due to the introduction of new immunosuppressive agents causes of mortality among renal transplant recipients have been changed. Nowadays, with the improvement of the long-term graft survival mortality occurrence due to malignancy has been increased with the incidence of 20% ten years after the kidney transplantation (1). Not only do the immunosuppressive drugs comprise defense against viral infections that act as malignancy promoters, but they also induce DNA damage and interfere with DNA repair mechanisms (2,3). The most common types of malignancies are skin cancer, post-transplant lymphoproliferative disease (PTLD) that may progress to lymphoma (4, 5). An increased incidence of malignant tumors is one of the major factors...
influencing the long-term survival of kidney transplant patients and therefore needs to be addressed carefully.

Here, we presented the case of plasma cell type lymphoma in the ileocecal region of a 45-year-old male kidney transplant patient who was on the immunosuppressive-based regimen for ten years. Although this case report was previously described (6), this paper focused primarily on immunosuppressive therapy.

CASE REPORT

The patient was 24-years-old when he underwent a unilateral nephrectomy due to left kidney calculus. Chronic insufficiency of the right kidney occurred in the following year, and the patient was treated with hemodialysis. Two years after nephrectomy, the patient received a transplant from living donor. After an episode of acute rejection of the transplanted graft, the patient was subjected to the appropriate therapy and allograft function was stabilized. Initially, patient has been on triple therapy with cyclosporine, azathioprine, and prednisone, according to previous standard transplantation practice. In 2004, the patient was converted to a newer regimen – firstly from azathioprine to mycophenolate mofetil and secondly from cyclosporine to therapy that included tacrolimus (1mg twice a day), mycophenolate mofetil (250 mg twice a day), and prednisone (10 mg once a day).

In September 2013, 20 years after the first nephrectomy, the patient was hospitalized again, this time due to sepsis and the signs of respiratory insufficiency. Moreover, profound inflammatory syndrome, hydronephrosis, pyelonephritis and right kidney atrophy, were observed. These complications precipitated the right nephrectomy in February 2014. The overall renal function was subsequently ascertained by the previously transplanted kidney. Multislice Computed Tomography (MSCT) of the abdomen showed visualized transplanted kidney of the following dimensions - 108x52x12mm and no signs of urinary obstruction. Above the upper half of the transplanted kidney, inter-intestinally homogeneous collection (size 60x40mm) was observed. Furthermore, areas of inflammation containing two formed abscesses with hypervascularized walls of 3.5 mm thickness were detected below the right lobe of the liver zone in the block with associated intestinal convolutions. "Staging" MSCT findings showed enlarged lymph node in right iliac fossa and right femoral fossa (Figure 1).

Surgical removal of visualized abscess collection was intended. However, on admission, laboratory values showed leukocytosis (17x10^9/L), anaemia (erythrocytes 3.53x10^9/L, hemoglobin 10.7g/L), elevated inflammatory markers (SE 125mm/h, CRP 188 mg/L and fibrinogen 5.6g/L), increased urea (15.8 mmol/L) and creatinine (231 μmol/L). After detailed preoperative assessment and preparation, laparotomy with midline incision was performed.

Additional exploration verified the existence of the block tumor of 10 cm in diameter, at the level of terminal ileum and cecum, accompanied with regional lymphadenopathy in the block with an appendix. The tumor was situated above well placed transplanted kidney without any infiltration. A urologist confirmed the normal findings of the kidney transplant and carefully removed tumor lesions with associated lymph nodes using standard right hemicolectomy with lymphadenectomy. Slices of the right colon, tumor changes in the block and lymph nodes were sent for further histopathological analysis.

Relatively well-circumscribed nodular tumor localized in the fatty tissue of retroperitoneum spreading to the wall of ascending colon, terminal ileum and appendix were described. The tumor had tough, solid texture, it was capsulated and clearly separated from adipose tissue (Figure 2). Right next to the tumor nodose were two enlarged lymph nodes measuring 25x20x15mm and 10x10x5mm in size, as well as the unclear infiltrate of 20x20x15mm in size, similar to a nodular tumor and located about 1 mm from the line of fat tissue resection. From the remaining adipose tissue, 6 more lymph nodes were isolated.

![Figure 1. MSCT findings showing enlarged lymph node in right iliac fossa (A) and in right femoral fossa (B).](image-url)
Histological sections of the tumor mass showed the proliferative change of organization from multinodular to diffuse, consisting of a relatively monomorphic population of large cells that might correspond to atypical lymphoid cells. The peripheral proliferation of small lymphoid cells was observed. In described nodular areas, large blastoid cells with various zones of necrosis, moderate mitotic index and atypical mitosis were detected. Tumor mass consisted of Reed-Sternberg cells which were CD15, CD30 and EBV-positive and PAX5, CD20, CD3, CD5, BCL2, Alk1 negative based on histopathological and immunohistochemistry findings. Obtained result indicated nodular sclerosis type of Hodgkin lymphoma.

The postoperative course was usual, and the patient was discharged in good general condition, metabolically and hemodynamically stable. Treatment involved modification of the immunosuppressive drug regimen (tacrolimus and MMF were discontinued), resection of localized disease, and chemotherapy.

All relevant information from the patient’s history is graphically presented in the timeline (supplementary material).

**DISCUSSION**

Patient survival time after renal and other solid organ transplantations has been substantially increased, partly due to modern immunosuppressive treatment. Nevertheless, the frequency of tumors is 2 to 4-fold higher when compared to the non-transplanted population, the most prevalent being Kaposi’s sarcomas, non-Hodgkin lymphomas, and non-melanoma skin cancers with the rate over 20 times greater than the one in general population (7, 8). In a study that included 2224 solid-organ transplant recipients who underwent transplant between 1985 and 2013, 27 of 2224 patients developed PTLD. The mean interval between transplant and diagnosis of PTLD was 65 months. Most patients with PTLD have extranodal involvement, with the gastrointestinal tract being the major site of clinical presentation-35% of all cases (9). In a retrospective single-center study conducted to assess the occurrence of de novo neoplasms in renal pati-
supplementary material.
Abstract

Following solid organ transplantation, the patient's management includes the provision of immunosuppressive therapy to the recipient. All kidney transplant recipients require lifelong immunosuppression. Regardless the improving survival following solid organ transplantation, post-transplant complications such as the development of malignancy due to immunosuppression remain to be an issue. One of the most common malignancies encountered in the post–solid organ transplant is lymphoproliferative disorder likely developed as a consequence of immunosuppression. We report a case of plasma cell type lymphoma in the ileocecal region of a 45-year-old male kidney transplant patient who was on a tacrolimus-based regimen for ten years. Although literature data indicate differently localized lymphoma as an adverse reaction to the long term use of tacrolimus, to our knowledge, this is the first described case of lymphoma in the ileocecal region. Serious adverse drug reactions and potential toxicity of tacrolimus emphasize the importance of finding the optimal balance between effective drug concentration and the risk associated with its use.